Infoscience

Journal article

Development of organometallic ruthenium(II) anticancer (RAPTA) drugs

A review. The systematic development of the RAPTA family of organometallic ruthenium(II) anticancer drugs contg. a monodentate 1,3,5-triaza-7-phosphatricyclo-[3.3.1.1]decane ligand and a h6-arene ligand is described.

Fulltext

Related material